

GROWLIFE, INC.

FORM 10-Q (Quarterly Report)

Filed 08/23/24 for the Period Ending 06/30/23

Address 11335 NE 122ND WAY

SUITE 105

KIRKLAND, WA, 98034

Telephone 866-781-5559

CIK 0001161582

Symbol PHOT

SIC Code 3231 - Glass Products, Made of Purchased Glass

Industry Heavy Machinery & Vehicles

Sector Industrials

Fiscal Year 12/31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 10-Q

×	QUARTERLY REPORT PURSUANT TO SECTIO	N 13 OF	R 15(d) OF THE SECURITIES	EXCHANGE AC	CT OF 1934				
	Fo		narterly period e 30, 2023						
	TRANSITION REPORT PURSUANT TO SECTIO	N 13 O	R 15(d) OF THE SECURITIES	EXCHANGE AG	CT OF 1934				
	For the transiti	on perio	od from to						
	Commis	ssion file	e number 000-50385						
GrowLife									
			Life, Inc. nt as specified in its charter)						
	Delaware		90-(0821083					
	(State or other jurisdiction of incorporation or organization)			Employer cation No.)					
	(Address of prin	Kirklan ncipal ex (866)	nd Way, Suite 105 d, WA 98034 ecutive offices and zip code) 781-5559 number, including area code)						
Sec	urities registered pursuant to Section 12(b) of the Act	•	number, meruang area code)						
Indi Exc	cate by check mark whether the registrant (1) has f hange Act of 1934 during the preceding 12 months (c) has been subject to such filing requirements for the	iled all or for su	ch shorter period that the registr		* /				
purs	cate by check mark whether the registrant has substant to Rule 405 of Regulation S-T (§232.405 of this strant was required to submit such files). Yes No	s chapte							
com	cate by check mark whether the registrant is a large appany, or an emerging growth company. See the depany", and "emerging growth company" in Rule 12b	finitions							
	Large accelerated filer Non-accelerated filer (Do not check if a smaller reporting company) Emerging growth company		Accelerated filer Smaller reporting company	□ ⊠					
	n emerging growth company, indicate by check manuplying with any new or revised financial accounting								
Indi	cate by check mark whether the registrant is a shell c	ompany	(as defined by Rule 12b-2 of the	e Exchange Act).	Yes □ No 🗷				
At A	At August 23, 2024, 55,384,656 shares of the issuer's common stock, \$0.0001 par value per share, was outstanding.								

TABLE OF CONTENTS

		Page Number
PART I	FINANCIAL INFORMATION	
ITEM 1	<u>Financial Statements (unaudited except as noted)</u>	3
	Consolidated Balance Sheets as of June 30, 2023, and December 31, 2022 (audited)	3
	Consolidated Statements of Operations for the three months and six months ended June 30, 2023 and 2022	4
	Consolidated Statements of Changes in Stockholders' Deficit for the three and six months ended June 30, 2023 and 2022	5
	Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022	6
	Notes to the Consolidated Financial Statements	7
ITEM 2	Management's Discussion and Analysis of Financial Condition and Results of Operation	24
ITEM 3	Quantitative and Qualitative Disclosures About Market Risk	27
ITEM 4	Controls and Procedures	28
PART II	OTHER INFORMATION	
ITEM 1	<u>Legal Proceedings</u>	29
ITEM 1A	Risk Factors	30
ITEM 2	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	30
ITEM 3	<u>Defaults Upon Senior Securities</u>	30
ITEM 6	Exhibits	31
	SIGNATURES	32
	-2-	

ITEM 1. FINANCIAL STATEMENTS

GROWLIFE, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

		,	December 31, 2022		
ASSETS	(Unaudite	:d)	((Audited)	
CURRENT ASSETS:					
Cash and cash equivalents	\$ 5	5,398	\$	94,208	
Accounts receivable	1	1,963			
Advances	12	2,144		160,000	
Inventory, net	21	1,089			
Total current assets	40),594		254,208	
Fixed assets, net of accumulated depreciation	98	3,322		_	
Intangible assets, net		_		_	
Operating lease right of use asset	61	1,700			
TOTAL ASSETS	\$ 200),616	\$	254,208	
LIABILITIES AND STOCKHOLDERS' (DEFICIT)					
CURRENT LIABILITIES:					
Accounts payable	811	1,264		850,618	
Accrued expenses	313	3,693		209,768	
Deferred revenue	11	1,788		_	
Due on asset purchase	102	2,216		_	
Notes payable- PPP/EIDL loans	803	3,659		716,252	
Notes payable	208	3,235		1,877,896	
Convertible notes payable, in default net	5,335	,499		2,225,888	
Convertible notes payable, net	295	5,873		97,628	
Derivative liability	3,614	1,677		2,686,892	
Operating lease right of use liability	62	2,076	_		
Total current liabilities	11,558	3,980		8,664,942	
STOCKHOLDERS' DEFICIT					
Series A Preferred stock - \$0.0001 par value, 10,000,000 shares authorized, 600 shares and					
1,800 shares issued and outstanding at 6/30/2023 and 12/31/2022, respectively		_		_	
Common stock - \$0.0001 par value, 740,000,000 shares authorized, 35,561,190 and					
7,083,254 shares issued and outstanding at 6/30/2023 and 12/31/2022, respectively	3	3,556		708	
Additional paid in capital	157,829	,045		156,385,473	
Accumulated deficit	(169,190			(164,796,915	
Total stockholders' deficit	(11,358	3,364)		(8,410,734	
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$ 200),616	\$	254,208	

GROWLIFE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

F	For the Three Months Ended			For the Six Months Ended			
Ju	ne 30, 2023	Jı	ine 30, 2022	Ju	ne 30, 2023	Ju	ne 30, 2022
\$	147,396	\$	_	\$	226,655	\$	_
	(43,738)		_		(84,731)		
	103,658		_		141,924		_
	(678,744)		(362,753)		(1,327,040)		(620,298)
	(575,086)		(362,753)		(1,185,116)		(620,298)
	(527,120)		(312,018)		(286,630)		(390,069)
	(1,787,643)		(570,612)		(2,444,789)		(371,110)
	(552,515)		_		(552,515)		_
							(170,285)
_	(2,801,912)	_	(864,733)		(3,208,934)		(931,464)
	(2.27(.000)		(1.227.400)		(4.204.050)		(1.551.5(2)
	(3,376,998)		(1,227,486)		(4,394,050)		(1,551,762)
		_					
	(3,376,998)		(1,227,486)		(4,394,050)		(1,551,762)
			(456.245)				(741-145)
		_		_		_	(741,145)
·		_	(456,345)				(741,145)
\$	(3,376,998)	\$	(1,683,831)	\$	(4,394,050)	\$	(2,292,907)
\$	(0.10)	\$	(1.19)	\$	(0.18)	\$	(1.64)
		\$	(0.44)	\$		\$	(0.78)
\$	(0.10)	\$	(1.63)	\$	(0.18)	\$	(2.42)
	_		_		_		_
_	32,315,356	_	1,035,116	_	24,979,492	_	948,844
	\$	\$ 147,396 (43,738) 103,658 (678,744) (575,086) (527,120) (1,787,643) (552,515) 65,366 (2,801,912) (3,376,998) ———————————————————————————————————	\$ 147,396 \$ (43,738) \$ 103,658 (678,744) (575,086) \$ (527,120) (1,787,643) (552,515) 65,366 (2,801,912) \$ (3,376,998) \$ \$ (3,376,998) \$ \$ \$ (0.10) \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	June 30, 2023 June 30, 2022 \$ 147,396 \$ — (43,738) — 103,658 — (678,744) (362,753) (575,086) (362,753) (527,120) (312,018) (1,787,643) (570,612) (552,515) — 65,366 17,897 (2,801,912) (864,733) (3,376,998) (1,227,486) — — (3,376,998) (1,227,486) S — (456,345) (456,345) \$ (3,376,998) \$ (1,683,831) \$ (0.10) \$ (0.44) \$ (0.10) \$ (0.10)	June 30, 2023 June 30, 2022 June 30, 2022 \$ 147,396	June 30, 2023 June 30, 2022 June 30, 2023 \$ 147,396 \$ — \$ 226,655 (43,738) — (84,731) 103,658 — 141,924 (678,744) (362,753) (1,327,040) (575,086) (362,753) (1,185,116) (527,120) (312,018) (286,630) (1,787,643) (570,612) (2,444,789) (552,515) — (552,515) — (552,515) 65,366 17,897 75,000 (2,801,912) (864,733) (3,208,934) (3,376,998) (1,227,486) (4,394,050) — (456,345) — (3,376,998) (1,227,486) (4,394,050) S — (456,345) — \$ (3,376,998) \$ (1,683,831) \$ (4,394,050) \$ (0.10) \$ (1.19) \$ (0.18) \$ (0.10) \$ (1.19) \$ (0.18) \$ (0.10) \$ (1.63) \$ (0.18)	June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2024 June 30, 2024 June 30, 2024 June 30, 2023 June 30, 2024 June 30,

GROWLIFE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited)

		ies A ed Stock	Commo	Additional Common Stock Paid in		Accumulated	Total Stockholders'
	Shares	Amount	Shares	Amount	Capital	Deficit	(Deficit)
Balance as of December 31, 2021	_	\$	786,351	\$ 79	\$ 154,380,348	\$ (160,314,038)	\$ (5,933,611)
Shares issued for convertible note conversions Net loss for the three months ended March 31, 2022			183,785	18 	694,797	(609,077)	694,815 (609,077)
Balance as of March 31, 2022	_	_	970,136	97	155,075,145	(160,923,115)	(5,847,873)
Shares issued for note commitments	_	_	20,000	5	99,543	_	99,548
Shares issued for convertible note conversions Fair value of warrants issued		_	160,000	16 —	198,881 27,417		198,897 27,417
Net loss for the three months ended June 30, 2022		(1,68		(1,683,831)	(1,683,831)		
Balance as of June 30, 2022		<u>\$</u>	1,180,136	\$ 118	\$ 155,400,986	\$ (162,606,946)	\$ (7,205,842)
Balance as of December 31, 2022	1,800	\$ —	7,083,254	\$ 708	\$ 156,385,473	\$ (164,796,915)	\$ (8,410,734)
Shares issued for convertible note conversions	_	_	7,700,00.	777	442,432	_	443,209
Shares issued for services Shares issued for note commitments		_	1,200,272	428 312	177,128 234,062		177,556 234,374
Shares issued for asset purchase		_		592	339,408		340,000
Net loss for the three months ended March 31, 2023						(1,017,052)	(1,017,052)
Balance as of March 31, 2023	1,800	_	28,177,856	2,817	157,578,503	(165,813,967)	(8,232,647)
Shares issued for convertible note conversions	_	_	5,600,000	560	199,128	_	199,688
Preferred shares converted to common shares	(1,200)		1,200,000	120	(120)	_	
Cashless exercise of warrants Net loss for the three months ended June 30, 2023			583,333		51,534	(3,376,998)	51,593 (3,376,998)
Balance as of June 30, 2023	600	<u>\$</u>	35,561,189	\$ 3,556	\$ 157,829,045	\$ (169,190,965)	\$ (11,358,364)

GROWLIFE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	.In	ne 30, 2023	ths Ended June 30, 2022	
	- 00	1110 00, 2020		1100, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:				
Net loss	\$	(4,394,050)	\$	(2,292,907
Loss from discontinued operations				741,145
Net loss from continuing operations		(4,394,050)		(1,551,762
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation expense		19,664		_
Amortization expense		110,502		_
Impairment of intangible assets		552,515		_
Non-cash interest expense		2,183,634		631,164
Shares issued for services		177,556		_
Change in fair value of derivative		286,630		96,230
Penalties incurred on debt		190,184		_
(Gain) on forgiveness of debt		(75,000)		(165,55)
Changes in operating assets and liabilities:				
Accounts receivable		(1,963)		_
Inventory		(7,500)		_
Advances		(2,560)		_
Accounts payable		110,645		16,80
Accrued expenses		103,926		5,00
Deferred revenue		11,788		_
Change in right of use asset and liability, net		376		_
Net cash used in operating activities		(733,653)		(968,11
Net cash (used) by operating activities by discontinued operations				(80,50
CASH USED BY OPERATING ACTIVITIES		(733,653)		(1,048,617
NACH ELONG EDOM DIVERSEDING A CENTRE				
CASH FLOWS FROM INVESTING ACTIVITIES:		(4.005)		
Purchase of fixed assets		(4,085)		(16.50)
Net cash (used) by investing activities by discontinued operations				(16,59)
CASH USED IN INVESTING ACTIVITIES		(4,085)		(16,590
ASH FLOWS FROM FINANCING ACTIVITIES:				
Proceeds from convertible debt, net of issuance costs		609,725		1,004,37
Proceeds from notes payable		251,948		1,001,57
Repayment of notes payable		(58,413)		_
Payments on purchase of assets		(118,002)		
Payments on asset purchase		(36,330)		_
Net cash (used) by financing activities by discontinued operations		(50,550)		(25,42
CASH PROVIDED BY FINANCING ACTIVITIES		648,928		978,950
ensitive (ibbb b) in which territings		0.0,520		,,,,,,,
IET CHANGE IN CASH AND CASH EQUIVALENTS		(88,810)		(86,25
ASH AND CASH EQUIVALENTS, beginning of period		94,208		363,963
ASH AND CASH EQUIVALENTS, end of period	\$	5,398	\$	277,700
Ion Cash Supplemental Information:				
Value of shares issued for convertible note conversion	\$	230,974	\$	2,502,59
Value of shares issued for liability settlement		_	\$	1,397,10
Value of shares issued for loan commitment fees	\$	81,890		_
Value of shares issued for purchase of assets	\$	340,000		_
Initial derivative discount	\$	245,153		_

GROWLIFE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

NOTE 1 – DESCRIPTION OF BUSINESS AND ORGANIZATION

GrowLife, Inc. ("GrowLife" or the "Company") is incorporated under the laws of the State of Delaware and is headquartered in Kirkland, Washington. The Company was founded in 2012 with the Closing of the Agreement and Plan of Merger with SGT Merger Corporation.

On June 2, 2022, GrowLife entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with Bridgetown Mushrooms, LLC, an Oregon limited liability company ("Seller") and Trevor Huebert ("Executive"), pursuant to which the Company would purchase and assume, certain assets, properties, rights and interests relating to the Seller's business ("Assets") which is the processing, marketing, storing, selling and distributing fresh and dried mushroom products ("Business"). On November 14, 2022, the parties executed the First Amendment to Asset Purchase Agreement ("First Amendment"), pursuant to which the parties amended the purchase price structure among other things. On January 6, 2023, the Company, Seller, and Executive consummated and closed the acquisition and acquired the Assets related to the Business (the "Closing Date") for cash consideration and additional consideration. On January 11, 2023, the Company and Seller entered into certain post-closing amendments including a Second Amendment to Asset Purchase Agreement ("Second Amendment"), further revising the purchase price structure and assumption of cert Seller debt obligations, a Pledge and Security Agreement and an Amended and Restated Promissory Note.

Founded in 2018 in Portland, Oregon, Bridgetown Mushrooms is currently one of the preeminent, organic producers of gourmet and functional mushrooms and mycology supplies in the Pacific Northwest, distributed through multiple commercial and consumer sales channels. It also develops and markets mushroom-based products nationwide as well as manufactures and sells mycology supplies to meet the large and growing demand for commercial mushroom farmers across the United States.

NOTE 2 - GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred net losses from continuing operations of \$4,394,050 and \$1,551,761 for the six months ended June 30, 2023 and 2022, respectively. Net cash used in operating activities from continuing operations was \$733,653 and \$1,539,075 for the six months ended June 30, 2023 and 2022, respectively.

The Company anticipates that it will record losses from operations for the foreseeable future. As of June 30, 2023, the Company's accumulated deficit was \$169,190,965. The Company has limited capital resources, and operations to date have been funded with the proceeds from private equity and debt financings. These conditions raise substantial doubt about our ability to continue as a going concern.

The Company believes that its cash on hand will be sufficient to fund our operations only until September 30, 2023. The Company needs additional financing to implement our business plan and to service our ongoing operations and pay our current debts. There can be no assurance that we will be able to secure any needed funding, or that if such funding is available, the terms or conditions would be acceptable to us. If we are unable to obtain additional financing when it is needed, we will need to restructure our operations, and divest all or a portion of our business. We may seek additional capital through a combination of private and public equity offerings, debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, and could increase our expenses and require that our assets secure such debt. Equity financing, if obtained, could result in dilution to the Company's then-existing stockholders and/or require such stockholders to waive certain rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, the Company may be required to delay, scale back, eliminate the development of business opportunities and our operations and financial condition may be materially adversely affected.

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS

Basis of Presentation – The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The preparation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles ("GAAP").

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its wholly owned and subsidiaries. Inter-Company items and transactions have been eliminated in consolidation.

Discontinue Operations – On December 29, 2022, the Company completed the Settlement and Mutual Release of a majority of its ownership in EZ-CLONE. The assets, liabilities and results of the EZ-CLONE business and the related cash flows have been reported as discontinued operations on the accompanying Balance Sheet and in the Consolidated Statements of Operations and Consolidated Statements of Cash Flows, respectively, through the date of sale. These changes have been applied to all periods presented. Unless otherwise noted, discussion within these notes to the consolidated financial statements relates to continuing operations. Refer to Note 4 for additional information on discontinued operations.

Cash and Cash Equivalents – We classify highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to \$250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit. At June 30, 2023 and December 31, 2022, the Company had no uninsured deposits.

Accounts Receivable – The Company grants credit to customers in the normal course of business. Accounts receivable consists of amounts due from customers. To date there has not been a requirement for a reserve against bad debts for any of the Bridgetown sales as collection has been occurring within thirty (30) days.

Revenue – The Company generates revenue from the sales of our products to food distributors, restaurants and bakeries and directly to consumers at farmers markets and via online transactions. Revenue is recognized upon shipment and is determined by the invoice amount. We do not provide the right to return unless there is a product issue, in which case we may provide replacement products. In some cases, we receive payment in advance of product delivery in which case the amount collected that has not been delivered is deferred and recognized as deferred revenue on the balance sheet.

Cost of Goods Sold – Cost of goods sold includes raw material costs and distribution costs for products sold; operating expenses related to products sold include compensation and benefits.

Inventory – Inventory are recorded on a first in first out basis. Inventory consists of raw materials, work in process and finished goods. The Company reviews its inventory on a periodic basis to identify products that are slow moving and/or obsolete, and if such products are identified, the Company records the appropriate inventory impairment charge at such time.

Property and Equipment – Equipment consists of machinery, equipment, and computer equipment, which are stated at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the relevant asset, generally 3 years.

Impairment of Intangibles – At the end of the second quarter of 2023 we recognized an impairment charge of \$553,000 related to purchase of Bridgetown Mushrooms. The value was determined by management to be impaired as a resulting from the reduced expectations for future sales as the result of a contract with a customer.

Fair Value Measurements and Financial Instruments – ASC Topic 820, Fair Value Measurement and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The hierarchy consists of three levels:

- Level 1 Quoted prices in active markets for identical assets and liabilities;
- Level 2 Inputs other than level one inputs that are either directly or indirectly observable; and.
- Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of June 30, 2023 and December 31, 2022 are based upon the short-term nature of the assets and liabilities. The Company's derivative financial instruments are considered Level 3 instruments. See Note 9.

Derivative Financial Instruments – Pursuant to ASC 815 "Derivatives and Hedging", the Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company then determines if embedded derivative must bifurcated and separately accounted for. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. The variable conversion features of the Convertible Notes Payable and certain warrants are considered derivatives, see Note 9. For derivative financial instruments, the Company uses the Binomial pricing model to value the derivative instruments at inception and on subsequent valuation dates. The Company uses the following assumptions when using the model: (i) risk-free interest rate of 1%; (ii) expected life of one year; (iii) expected dividend of 0%; and (iv) expected volatility ranging from 140% – 184%. The classification of derivative instruments including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.

In August 2020, the FASB issued ASU No. 2020-06, *Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40).* The amendment is meant to simplify the accounting for convertible instruments by removing certain separation models in subtopic 470-20 for convertible instruments. The amendment also changed the method used to calculate dilutes EPS for convertible instruments and for instruments that may be settled in cash. The amendment is effective for years beginning after December 15, 2023, with early adoption for years beginning after December 15, 2020 including interim periods for those fiscal years. The Company adopted ASU No. 2020-06 in the first quarter of 2022. The adoption did not have an impact on the Company's financial statements.

Leases — We lease all our office space used to conduct our business. Such leases expire April 30, 2024. We adopted ASC 842 effective January 1, 2019. For contracts entered into on or after the effective date, at the inception of a contract we assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.

The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, our secured incremental borrowing rate for the same term as the underlying lease. For our real estate and other operating leases, we use our secured incremental borrowing rate of 10%.

Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, and payments for early termination options unless it is reasonably certain the lease will not be terminated early.

Our real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement and separated into lease and non-lease components based on the initial amount stated in the lease or standalone selling prices. Lease components are included in the measurement of the initial lease liability. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability.

Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense.

Actual lease payments through the end of the term of the lease amount to \$64,420. \$38,652 is due by December 31, 2023 with the balance of \$25,768 due by April 30, 2024.

Stock Based Compensation – We have share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options to purchase shares of our common stock at the fair market value at the time of grant. Stock-based compensation cost is measured by us at the grant date, based on the fair value of the award, over the requisite service period using an estimated forfeiture rate. For options issued to employees, we recognize stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock options and stock to non-employees and other parties are accounted for in accordance with the ASC 718.

Convertible Securities – Based upon ASC 815-15, we have adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities issued subsequent to September 30, 2015. The Company evaluates its contracts based upon the earliest issuance date.

Net Loss Per Share – Under the provisions of ASC Topic 260, "Earnings per Share," basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The common stock equivalents have not been included as they are anti-dilutive.

As of June 30, 2023 and December 31, 2022, there were warrants for the purchase of 1,951,111 and 7,917,222 shares of common stock, respectively, at a \$0.203 average exercise price. On April 1, 2023 Fourth Man LLC executed a cashless exercise of the 625,000 warrants granted on February 2, 2023 in connection with the issuance of convertible debt by the Company. The cashless exercise resulted in the issuance of 583,333 common shares by the Company. In addition, we have an unknown number of common shares to be issued under the convertible notes financing agreements and warrants because the number of shares ultimately issued depends on the price at which the holder converts its debt to shares and exercises its warrants. The lower the conversion or exercise prices, the more shares that will be issued to the holder upon the conversion of debt to shares. The Company will not know the exact number of shares of stock issued to the holder until the debt is actually converted to equity.

As of June 30, 2023 and December 31, 2022, there were no stock option grants outstanding. In addition, the Company has an unknown number of common shares to be issued under the various convertible debt financing agreements. Also, certain agreements will allow for conversion should the Company default on terms in the agreements.

Dividend Policy – The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of our business. Our future dividend policy will be determined by the board of directors on the basis of various factors, including our results of operations, financial condition, capital requirements and investment opportunities.

Use of Estimates – In preparing these consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates and assumptions included in our consolidated financial statements relate to the valuation of long-lived assets, estimates of sales returns, inventory reserves and accruals for potential liabilities, and valuation assumptions related to derivative liability, equity instruments and share based compensation.

Recent Accounting Pronouncements

Based on the Company's review of accounting standard updates issued, there have been no other newly issued or newly applicable accounting pronouncements that have had, or are expected to have, a significant impact on the Company's consolidated financial statements.

NOTE 4 – BUSINESS COMBINATIONS, ACQUISITION PAYABLE AND DISCONTINUED OPERATIONS

Business Combination of Bridgetown Mushrooms

On June 2, 2022, GrowLife, Inc., a Delaware corporation ("Company" or "Purchaser") entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with Bridgetown Mushrooms, LLC, an Oregon limited liability company ("Seller") and Trevor Huebert ("Executive"), pursuant to which the Company would purchase and assume, certain assets, properties, rights and interests relating to the Seller's business ("Assets") which is the processing, marketing, storing, selling and distributing fresh and dried mushroom products ("Business"). On November 14, 2022, the parties executed the First Amendment to Asset Purchase Agreement ("First Amendment"), pursuant to which the parties amended the purchase price structure among other things. On January 6, 2023, the Company, Seller, and Executive consummated and closed the acquisition and acquired the Assets related to the Business (the "Closing Date") for cash consideration and additional consideration. On January 11, 2023, the Company and Seller entered into certain postclosing amendments including a Second Amendment to Asset Purchase Agreement ("Second Amendment"), further revising the purchase price structure and assumption of cert Seller debt obligations, a Pledge and Security Agreement ("Pledge Agreement"), and an Amended and Restated Promissory Note ("Note"). The cash consideration, paid prior to the Closing Date, was in the aggregate amount of \$157,000, the additional consideration consists of: (i) \$43,000 in the form of cancellation and forgiveness of the indebtedness owed to Purchaser by Seller under a secured promissory note dated May 19, 2022 (the "Prior Loan"); (ii) \$138,546 in the form of promissory note, which was payable in installments of (1) \$38,546 on January 31, 2023, (2) \$50,000 on February 28, 2023, and (3) \$50,000 on June 30, 2023; (iii) \$340,000 in the form of shares of restricted shares of the common stock, which as of the Closing Date was equal to an aggregate of 5,923,345 (the "Stock Consideration"), were issued and distributed pursuant to the terms and conditions of the Asset Purchase Agreement, and (iv) the assumption of \$161,546 of debt which is secured by the assets of the Seller.

The assets acquired from Seller and Executive included tangible assets, intellectual property, registrations and approvals, inventory, data, records, and certain other assets. The Asset Purchase Agreement contains customary representations and warranties and covenants by each party. Both parties are obligated, subject to certain limitations, to indemnify the other under the Asset Purchase Agreement for certain customary and other specified matters, including breaches of representations and warranties, breaches of covenants and for certain liabilities and third-party claims. The purchase allocation was accounted for as follows:

Fair value of consideration transferred:

Tall value of consideration transferred.		
Cash paid in advance	\$	150,416
Secured debt assumed		161,546
Note payable to seller		138,546
Value of common shares issued		340,000
	\$	790,508
Fair value of assets acquired and liabilities assumed:		
Inventory	\$	13,589
Fixed assets		113,902
Intangible assets		663,017
	2	790,508
	Φ	770,300

The Company is unable to provide comparable June 30, 2022 pro-forma financials for Bridgetown due to the state of the underlying records.

Acquisition and Disposition of EZ-CLONE Enterprises, Inc.

On October 15, 2018, the Company closed the Purchase and Sale Agreement with EZ-CLONE Enterprises, Inc. ("EZ-CLONE"), a California corporation (the "Agreement"). The total purchase price was \$4 million of which \$1,500,000 is payable in cash and \$2.5 million payable in stock. At closing, we paid 51% of this amount totaling \$2,040,000 via a (i) a cash payment of \$645,000; and (ii) the issuance of 715,385 restricted shares of our common stock valued \$1,395,000. The Agreement called for the Company, upon delivery of the remaining 49% of EZ-Clone stock, to acquire such stock within one year for \$1,960,000, payable as follows: (i) a cash payment of \$855,000; and (ii) the issuance of Company's common stock at a value of \$1,105,000.

On November 5, 2019, the Company amended the Agreement with one 24.5% shareholder of EZ-CLONE to extend the date to purchase the remaining 49% of stock of EZ-CLONE in exchange for a 20% extension fee (a total of \$171,000 for the 49% or \$85,500 for each 24.5% shareholder) of the \$855,000 cash payable at the earlier of the closing of \$2,000,000 in funding or nine months (July 2020). The Company did not close the purchase of the remaining 49% of stock of EZ-CLONE by the extended deadline.

On September 15, 2020, the Company received notice that William Blackburn and Brad Mickelsen ("Plaintiffs"), minority shareholders of EZ-CLONE Enterprises, Inc., a majority owned subsidiary of the Company, filed a complaint against the Company in the Superior Court of California, County of Sacramento ("Complaint") for claims related to breach under the Purchase and Sale Agreement dated October 15, 2018 between the Company and Plaintiffs. As of December 4, 2020, the Company's officers were dismissed from the case. The Plaintiffs are seeking rescission of the Purchase and Sale Agreement, unspecified damages in excess of ten thousand dollars, and other equitable relief. See Note 17 for description of Legal Proceedings.

The Company accounted for the acquisition in accordance with ASC 805, "Business Combinations". ASC 805 defines the acquirer in a business combination as the entity that obtains control of one or more businesses in a business combination and establishes the acquisition date as the date that the acquirer achieves control. ASC 805 requires an acquirer to recognize the assets acquired, the liabilities assumed, and any non-controlling interest in the acquiree at the acquisition date, measured at their fair values as of that date.

For accounting purposes, from October 15, 2018 through December 29, 2022 the Company consolidated EZ-Clone given their control and recorded its obligation to acquire the remaining interest in EZ-Clone. The Company considered EZ-Clone to be 100% owned.

Settlement Agreement with EZ-CLONE Enterprises, Inc.

On December 29, 2022, to avoid the costs, risks, and uncertainties inherent in litigation, the Company, EZ-CLONE and William Blackburn (collectively, the "EZ Parties") entered into that certain Settlement Agreement and General Mutual Release (the "Settlement Agreement) whereby the Company and the EZ Parties agreed to settle, compromise, fully, and finally resolve all the disputes and potential disputes between them pursuant to the terms and conditions of the EZ Agreement. Among other things, the Company will relinquish such number of shares such that the Company owns an aggregate number of EZ-CLONE shares less than 20% and in exchange EZ-CLONE assumed the obligations of the Company under the lease for the real property on which EZ-CLONE conducts its business. Both Parties agree that the terms of the Settlement Agreement are fair and equitable and that all such disputes, known or unknown, between them are forever discharged and extinguished. By agreement of the parties the Settlement Agreement is deemed performed and complete as of December 31, 2022. As a result of the Settlement agreement, the Company deconsolidated its investment in EZ-Clone, and recognized a gain on deconsolidation of \$1.7 million. The gain on the deconsolidation was primarily the result of the derecognition of the \$2.1 million owed in connection with the acquisition of EZ-CLONE. The Company now records its investment in EZ-Clone using the cost method of accounting and has valued its minority interest at zero based on the projected operations in the near future and unlikely ability to liquidate the Company's remaining investment interest.

Summarized Discontinue Operations Financial Information

The following table summarizes the major line items for the EZ-CLONE business that are included in the Consolidated Statements of Operations:

	Mo	the Three nths Ended ne 30, 2022	For the Six Months Ended June 30, 2022		
Net Revenue	\$	314,894	\$	1,175,250	
Cost of goods sold		(163,883)		(606,546)	
Gross Profit		151,011		568,704	
Operating expenses		(718,356)		(1,454,688)	
(Loss) from operations		(567,345)		(885,984)	
Non-operating (income) expense				1,160	
Profit (loss) before income taxes		(567,345)		(887,144)	
Income taxes		(111,000)		(146,000)	
Net income (loss)	\$	(456,345)	\$	(741,144)	

NOTE 5 -INVENTORY

Inventory at June 30, 2023 consisted of the following:

Raw materials	\$ 7,918
Work in progress	2,902
Finished goods	 10,269
	\$ 21,089

NOTE 6 - PROPERTY AND EQUIPMENT

Property and equipment as of June 30, 2023 consists of the following:

	Estimated Life	
Machinery and equipment	3 Years	\$ 113,901
Computers	3 Years	4,085
Total		117,986
Less accumulated depreciation		(19,664)
		\$ 98,322

Total depreciation expense was \$9,832 and \$19,664 for the three months and six months ended June 30, 2023, respectively.

NOTE 7 – INTANGIBLE ASSETS

Intangible assets as of June 30, 2023 consisted of the following:

	Estimated Life	
Intangible assets	3 Years	\$ 663,017
Less accumulated amortization		(110,502)
Less impairment		(552,515)
		\$

Total amortization expense was \$55,251 and \$110,502 for the three months and six months ended June 30, 2023, respectively. During the three months ended June 30, 2023 management determined that the intangible assets which result from the Bridgetown were deemed to have no future value as a result of operations not meeting the forecasted results of operations used in the determination of the original consideration provided in the transaction.

NOTE 8 -NOTES PAYABLE

Notes Payable as of June 30. 2023 consisted of the following:

	Interest Rate		Principal		Principal		Principal		Principal		Principal		Principal		Principal		Principal		Accrued Interest	Di	iscount	ı	Balance
Government Assistance Notes in Default																							
Paycheck Protection Program (In Default)	1%	\$	362,500	\$	11,995	\$	_	\$	374,495														
Paycheck Protection Program (In Default)	1%		337,050		8,317		_		345,367														
Small Business Administration	3.75%		79,600		4,197		_		83,797														
		\$	779,150	\$	24,509	\$	_	\$	803,659														
Promissory Notes						-																	
Promissory notes	5%		111,151		2,448	\$	_		113,599														
Arin Funding	36%		94,636		_		_		94,636														
		\$	205,787	\$	2,448	\$	_	\$	208,235														
	13																						

	Interest		Accrued					
	Rate	Principal	Interest		nterest Discount		Balance	
Convertible Promissory Notes in Default	<u> </u>							
Silverback 2-12-21	22%	\$ 1,044,889	\$	64,409	\$	_	\$	1,109,298
Dublin Holdings 2-6-21	8%	446,894		9,838		_		456,732
Dublin Holdings 8-25-21	8%	335,000		53,949		_		388,949
Dublin Holdings 11-5-21	8%	225,000		32,031		_		257,031
1800 Diagonal 10-17-22	22%	132,000		17,848		_		149,848
1800 Diagonal 11-14-22	22%	90,750		11,631		_		102,381
Quick Capital 11-2-22	12%	95,556		14,391		_		109,947
Coventry Enterprises 11-9-22	18%	226,834		9,373		_		236,207
AJB Capital 12-29-22	24%	1,870,000		69,651		_		1,939,651
1800 Diagonal 1-13-23	22%	89,587		1,546		_		91,133
Fourth Man 2-2-23	16%	125,000		6,883		_		131,883
Fourth Man 3-23-23	16%	113,773		405		_		114,178
One44 Capital 3-28-23	24%	150,000		8,478		_		158,478
1800 Diagonal 3-28-23	22%	81,337		8,446		_		89,783
		\$ 5,026,620	\$	308,879	\$	_	\$:	5,335,499
Convertible Promissory Notes								
L&H 1-19-23	5%	\$ 75,000	\$	1,683	\$	(9,461)	\$	67,222
Individuals	10%	250,000		2,717		(24,066)		228,651
		\$ 325,000	\$	4,400	\$	(33,527)	\$	295,873
		,	<u>-</u>	,	É	()/	÷	,

Notes Payable as of December 31, 2022 consisted of the following:

Interest		Accrued			
Rate	Principal	Interest	Discount	Balance	
1%	\$ 362,500	\$ 10,117	\$ —	\$ 372,617	
1%	337,050	6,585	_	343,635	
	\$ 699,550	\$ 16,702	\$ —	\$ 716,252	
5%	\$ 127,500	\$ 4,847	\$ —	\$ 132,347	
10%	250,000	3,144	(140,795)	112,349	
10%	1,870,000	_	(236,800)	1,633,200	
	\$ 2,247,500	\$ 7,991	\$ (377,595)	\$ 1,877,896	
	1% 1% 5% 10%	Rate Principal 1% \$ 362,500 1% \$ 337,050 \$ 699,550 5% \$ 127,500 10% \$ 250,000 10% \$ 1,870,000	Rate Principal Interest 1% \$ 362,500 \$ 10,117 1% \$ 337,050 6,585 \$ 699,550 \$ 16,702 5% \$ 127,500 \$ 4,847 10% 250,000 3,144 10% 1,870,000 —	Rate Principal Interest Discount 1% \$ 362,500 \$ 10,117 \$ — 1% \$ 337,050 6,585 — \$ 699,550 \$ 16,702 \$ — 5% \$ 127,500 \$ 4,847 \$ — 10% 250,000 3,144 (140,795) 10% 1,870,000 — (236,800)	

	Interest Rate	Principal	Accrued Interest	Discount	Balance	
Convertible Promissory Notes in Default	Kate	Тіпсіраі	Interest	Discount	Datatice	
Silverback 2-12-21	22%	\$ 995,130	\$ 117,520	\$ —	\$ 1,112,650	
Dublin Holdings 2-6-21	8%	491,643	1,080	_	492,723	
Dublin Holdings 8-25-21	8%	335,000	38,616	_	373,616	
Dublin Holdings 11-5-21	8%	225,000	21,899	_	246,899	
		\$ 2,046,773	\$ 179,115	\$ —	\$ 2,225,888	
Convertible Promissory Notes						
1800 Diagonal 10-17-22	8%	\$ 88,000	\$ 622	\$ (36,338)	\$ 52,284	
1800 Diagonal 11-14-22	8%	60,500	1,458	(27,791)	34,167	
Quick Capital 11-2-22	12%	95,556	1,898	(86,277)	11,177	
		\$ 244,056	\$ 3,978	\$ (150,406)	\$ 97,628	

Government Assistance Notes Payable

On April 17, 2020, the Company received \$362,500 under the Paycheck Protection Program of the U.S. Small Business Administration's (SBA) 7(a) Loan Program pursuant to the Coronavirus, Aid, Relief and Economic Security Act (CARES Act), Pub. Law 116-136, 134 Stat. 281 (2020). The interest rate is one percent (1%). The loan was due April 2022.

On February 3, 2021, the Company received \$337,050 under the Paycheck Protection Program of the U.S. Small Business Administration's (SBA) 7(a) Loan Program pursuant to the Coronavirus, Aid, Relief and Economic Security Act (CARES Act), Pub. Law 116-136, 134 Stat. 281 (2020). The interest rate is one percent (1%). The loan was due February 2023.

As part of the assets purchased from Bridgetown Mushrooms the Company assumed a loan from the Small Business Administration in the amount of \$79,600. The note has an interest rate of 3.75%. The note is secured by certain assets acquired from Bridgetown Mushrooms and is due June 5, 2050.

Promissory Notes

Promissory Notes

At June 30, 2023 the Company had outstanding unsecured borrowings from four parties which total \$208,235. Included in this total the Company assumed a secured note from an individual in connection with the asset purchase. The balance of this note was \$38,502 at June 30, 2023. This note is secured by specific equipment acquired in the acquisition of Bridgetown.

Arin Funding

On March 9, 2023 and March 29, 2023 the Company borrowed \$105,000 from Arin Funding, less transaction fees of \$1,550. The notes are secured by future sales in the total amount of \$149,550. The notes are being repaid by daily debits against our bank account and are to be repaid within nine months of the issuance date. On June 30, 2023, \$94,637 of these notes remains outstanding.

Convertible Promissory Notes

The various Convertible Notes are In Default under the terms of the agreements. Defaults include not filing with the SEC on a timely basis, or missed interest/principal payments. As a result, the interest rate increased for a number of such notes, plus any discount associated with the derivative liability calculation must be written off. The impact on these notes was recorded during the second quarter of 2023 as the Company did not file the Form 10-K for 2022 when due.

Silverback Capital Corporation

The 22% Notes are convertible at the holder's option into the Company's common stock at 65% of the lower of \$1.35 or 50% of the average of the lowest three days stock price during the previous twenty trading days. During the six months ended June 30, 2023, Silverback converted principal and interest of \$175,973 into 8,495,000 shares of our common stock at an average per share conversion price of \$0.021. On April 17, 2023 Silverback issued the Company a Default Notice for not filing the Form10-K for 2022 on a timely basis which resulted in increasing the debt by \$49,757.

Dublin Holdings

On August 25, 2021, and on November 5, 2021, the Company entered into the following agreements with Bucktown: (i) Securities Purchase Agreements; (ii) Secured Convertible Promissory Notes; and (iii) Security Agreements. The total amount for these Notes is \$560,000; the Note carries an aggregate original issue discount of \$50,000 and a transaction expense amount of \$10,000. The Notes have an interest rate of eight percent (8%). The Note is convertible, at Bucktown's option, into the Company's common stock at \$0.10 per share ("Lender Conversion Price"), subject to adjustment as provided for in the Note. However, in the event the Market Capitalization (as defined in the Note) falls below the Minimum Market Capitalization the Lender Conversion Price shall equal the lower of the Lender Conversion Price and the Market Price as of any applicable date of Conversion. During the six months ended June 30, 2023, Dublin converted principal and interest of \$55,000 into 1,948,627 shares of our common stock at an average per share conversion price of \$0.028.

On June 30, 2023 Dublin Holdings assumed the three notes from Bucktown. The were no changes to any of the debt agreements.

The Company's obligation to pay the Notes, or any portion thereof, are secured by all the Company's assets.

1800 Diagonal Lending LLC

On October 17, 2022, and on November 11, 2022, the Company entered into the following agreements with 1800 Diagonal Lending LLC: (i) Securities Purchase Agreements; and (ii) Convertible Promissory Notes. The total amount for these Notes is \$148,500; the Note carries an aggregate original issue discount of \$13,500 and a transaction expense amount of \$7,000. The Notes are due one year from the issuance date. The Notes have an interest rate of eight percent (8%). Upon default by the Company the interest rate increases to twenty-two percent (22%). After six months from the issue date, the Notes are convertible, at 1800 Diagonal's option, into the Company's common stock at seventy-five percent (75%) of the average of the lowest three days closing price over the prior fifteen trading days.

On April 17, 2023 1800 Diagonal issued the Company a Default Notice for not filing the Form10-K for 2022 on a timely basis which resulted in increasing the October 17, 2022 debt by \$44,000 and the November 11, 2022 debt by \$31,289.

Quick Capital LLC

On November 2, 2022, the Company entered into the following agreements with Quick Capital LLC: (i) Note Purchase Agreement, (ii) Convertible Promissory Note, and (iii) Common Stock Purchase Warrant. The total amount for this Note is \$95,555; the Note carries an aggregate original issue discount of \$9,555. and a transaction expense amount of \$11,000. Additionally, under the Note Purchase Agreement the Company agreed to issue 100,000 shares of Common Stock (the "Commitment Shares") to the Investor as additional consideration for the Note. The Note is due eight months from the issuance date. The Note has an interest rate of twelve percent (12%). Upon default by the Company the interest rate increases to twenty-four percent (24%). The Note is convertible, at Quick Capital's option, into the Company's common stock at the lower of \$0.06 or seventy-five percent (75%) of the average of the lowest two days closing price over the prior fifteen trading days. Upon default by the Company the conversion price is adjusted to \$0.03 per share. The Warrant agreement allows for Quick Capital to purchase 1,911,111 shares at \$0.05 per share and has a five-year term. No payments were made by the Company since inception of this Note.

Coventry Enterprises LLC

On November 9, 2022, the Company entered into the following agreements with Coventry Enterprises LLC: (i) Securities Purchase Agreement; and (ii) Promissory Note. The total amount of the Note is \$250,000; the Note carries an aggregate original issue discount of \$50,000. Additionally, under the Securities Purchase Agreement the Company agreed to issue 200,000 shares of Common Stock and 1,800 shares of Preferred Stock which is convertible into 1,800,000 shares of Common Stock (the "Commitment Shares") to the Investor as additional consideration for the Note. The Note carries an interest rate of ten percent (10%) per annum and matures on November 9, 2023. Upon default by the Company the interest rate increases to eighteen percent (18%). Upon default by the Company, the Note is convertible by Coventry into the Company's common stock at ninety percent (90%) of the lowest trading price during the previous twenty trading days. The Note requires monthly payments of \$39,286 commencing April 9, 2023 and ending November 9, 2023. The Company made one payment in April 2023.

On April 26, 2023 Coventry converted 1,200 preferred shares into 1,200,000 shares of the Company's common stock.

AJB Capital Investments LLC

On May 17, 2022, the Company entered into the following agreements with AJB Capital Investments LLC: (i) Securities Purchase Agreement; and (ii) Promissory Note; (iii) Common Stock Purchase Warrant; and (iv) Security Agreement. The total amount of the Note is \$750,000; the Note carries an aggregate original issue discount of \$75,000 and transaction expenses of \$56,000. The Note carries an interest rate of ten percent (10%) per annum and matures on November 17, 2022. Should the Note be extended at that time the interest rate increases to fifteen percent (15%). Upon default by the Company, the Note is convertible by AJB Capital into the Company's common stock at the lesser of the lowest trading price during the previous twenty trading days either (i) ending on the date of conversion of the Note or (ii) the date of the Note. In connection with executing the Note the Company issued 50,000 shares of its common stock as an initial commitment fee. Should the Note be extended, the Company was obligated to issue an additional 33,333 shares as an extension commitment fee. The Warrant agreement allows for AJB to purchase 6,000,000 shares at \$0.05 per share and has a five-year term. The Company recorded an original issue discount of approximately \$519,250 related to the original issue discount, shares issued and warrants. This Note was refinanced with AJB on December 29, 2022.

On September 28, 2022, the Company entered into the following agreements with AJB Capital Investments LLC: (i) Securities Purchase Agreement; and (ii) Promissory Note; and (iii) Security Agreement. The total amount of the Note is \$220,000; the Note carries an aggregate original issue discount of \$20,000 and transaction expenses of \$5,000. The Note carries an interest rate of ten percent (10%) per annum and was to mature on May 28, 2023. Should the Note be extended at that time the interest rate increases to fifteen percent (15%). Upon default by the Company, the Note is convertible by AJB Capital into the Company's common stock at the lesser of the lowest trading price during the previous twenty trading days either (i) ending on the date of conversion of the Note or (ii) the date of the Note. In connection with executing the Note the Company issued 53,333 shares of its common stock as an initial commitment fee. Proceeds from the Note in the amount of \$151,048 were used to pay off the outstanding balance due 1800 Diagonal. This Note was refinanced with AJB on December 29,2022.

On December 29, 2022, the Company entered into the following agreements with AJB Capital Investments LLC: (i) Securities Purchase Agreement; and (ii) Promissory Note; and (iii) Security Agreement. The total amount of the Note is \$1,870,000; the Note carries an aggregate original issue discount of \$168,300 and transaction expenses of \$30,000. The Note carries an interest rate of ten percent (10%) per annum and matures on June 29, 2024. Should the Note be extended at that time the interest rate increases to fifteen percent (15%). Upon default by the Company, the Note is convertible by AJB Capital into the Company's common stock at the lesser of the lowest trading price during the previous twenty trading days either (i) ending on the date of conversion of the Note or on (ii) the date of the Note. In connection with executing the Note the Company issued 700,000 shares of its common stock as an initial commitment fee. \$970,000 of this Note was used to replace the Notes dated May 17 and September 28, 2022. \$580,000 of this Note was used to repurchase the 50,000 and 53,333 commitment shares issued in obtaining the May 17 and September 28, 2022 Notes per those Securities Purchase Agreements. Such repurchased shares were cancelled. The Company expensed the \$580,000 as additional interest expense in recording this Note as debt issuance costs related the May and September AJB Note Agreements. The Note requires monthly payments as follows: (i) \$15,583 from February through June 2023, (ii) \$115,759 from July 2023 through January 2024, and (iii) \$230,750 from February through June 2024. The Company made three payments during the three months ended March 31, 2023 and one payment during the three months ended June 30, 2023.

1800 Diagonal LLC

On January 11, 2023, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with 1800 Diagonal Lending LLC, a Virginia limited liability company (the "Investor"), pursuant to which the Company issued 1800 Diagonal a promissory note in the principal amount of \$88,200 (the "Note"). The Note carries a one-time interest charge of twelve percent (12%) (the "Interest Rate") which was applied on the issuance date to the principal (22% upon the occurrence of an event of default) and has a maturity date of January 11, 2024. The Note included an original issue discount of \$9,450 and transaction expenses of \$3,750 and was issued for an aggregate of \$75,000. The Note was funded by the Investor on January 13, 2023.

The Note requires that the Company make monthly payments for accrued interest and outstanding principal, which shall be paid in ten (10) payments each in the amount of \$9,878 (a total payback to the Holder of \$98,784). The first payment shall be due March 1, 2023, with nine (9) subsequent payments each month thereafter. The Company shall have a five (5) day grace period with respect to each payment. The Company has right to accelerate payments or prepay in full at any time with no prepayment penalty. The Company has made each payment through June 30, 2023.

The Investor may in its option, at any time following an Event of Default, as defined in the Note, convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock at a conversion price per share equal to 75% of the lowest daily volume weighted average price ("VWAP") of our common stock during the 10 trading days prior to the date of conversion. Due to this conversion feature this note was not included in determining the derivative liability.

L&H

On January 19, 2023, the Company issue a convertible note in the amount of \$75,000 in lieu of payment of amounts due for professional services. The note has an interest rate of 5% and is due January 19, 2024. Should the note plus accrued and unpaid interest not be repaid by the date the holder has the right to convert the balance at the lower of \$0.0529 or the closing price on the date before the conversion date. In addition, the Company issued 812,025 shares of common stock as payment for \$42,956 of services previously provided.

Fourth Man LLC

On February 1, 2023 (the "Issue Date"), Growlife, Inc. a Delaware corporation (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Fourth Man LLC, a Nevada limited liability company (the "Investor"), pursuant to which the Company sold Investor a convertible Promissory Note (the "Note") in the principal aggregate amount of \$125,000, which carries an original issue discount in the amount of \$21,250, plus \$10,762 in transaction fees accordingly the Company received proceeds of \$92,987 of the purchase price. The Purchase Agreement and the Note require the Company to pay interest on the unpaid Principal Amount at the rate of ten percent (10%) (the "Interest Rate") per annum (with the understanding that the first twelve months of interest (equal to \$12,500) shall be guaranteed and earned in full as of the Issue Date). The Note is due and payable, in full, as of the maturity date, which is twelve (12) months from the Issue Date. The Note may not be prepaid or repaid in whole or in part and the Investor has the right, at any time on or following the Issue Date, to convert all or any portion of the outstanding and unpaid Principal Amount and interest into fully paid and non-assessable shares of the Company's common stock. The per share conversion price into which Principal Amount and interest under the Note is \$0.035 per share, subject to adjustment as provided in the Note which effectively allows for a variable conversion rate. Additionally, the Note may not be converted into shares of our common stock if such conversion would result in the Investor, or its affiliates owning an aggregate of more than 4.99% of the then outstanding shares of our common stock.

On March 21, 2023 (the "Issue Date"), Growlife, Inc. a Delaware corporation (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Fourth Man LLC, a Nevada limited liability company (the "Investor"), pursuant to which the Company sold Investor a Convertible Promissory Note (the "Note") in the principal aggregate amount of \$125,000, which carries an original issue discount in the amount of \$21,250, and \$10,762 of transactions costs accordingly the Company received \$92,987 of the purchase price. Additionally, under the Purchase Agreement the Company agreed to issue 3,125,000 shares of Common Stock (the "Commitment Shares") to the Investor as additional consideration for the purchase of the Note, which shall be earned in full as of the Closing Date, March 23, 2023. The Purchase Agreement and Note require the Company to pay interest on the unpaid Principal Amount at the rate of ten percent (10%) (the "Interest Rate") per annum (with the understanding that the first twelve months of interest (equal to \$12,500) shall be guaranteed and earned in full as of the Issue Date). The Note is due and payable, in full, as of the maturity date, which is twelve (12) months from the Issue Date. Upon default, the Note provides the debt may be converted into shares of the Company. The Conversion Price is \$0.01 per share, subject to adjustment as provided for in the Note which effectively allows for a variable conversion rate. Conversions are subject to adjustment for any stock dividend, stock split, stock combination, rights offerings, reclassification, or similar transaction that proportionately decreases or increases the common stock. On June 22, 2023 the Company made a payment of \$15,938 on this loan.

Additionally and in connection with the issuance of the Note, the Company issued the Commitment Shares (as defined in the Purchase Agreement) to Investor as a commitment fee, provided, however, that 2,125,000 of the Commitment Shares (subject to equitable adjustments resulting any stock dividend, stock split, stock combination, rights offerings, reclassification, or similar transaction that proportionately decreases or increases the Common Stock) may be cancelled and extinguished if the Note is fully repaid and satisfied on or prior to June 21, 2023. The fair value of the 3,125,000 shares issued was expensed upon issuance.

1800 Diagonal Lending LLC

On March 24, 2023, Growlife, Inc. a Delaware corporation (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with 1800 Diagonal Lending LLC, a Virginia limited liability company (the "Investor"), pursuant to which the Company sold 1800 Diagonal a promissory note in the principal amount of \$54,725 (the "Note"). The Note carries an interest charge of eight percent (8%) (the "Interest Rate") which was applied on the issuance date to the principal (22% upon the occurrence of an event of default) and has a maturity date of March 24, 2024. The Note included an original issue discount of \$9,725 and transaction expenses of \$4,250 and was purchased for an aggregate of \$40,750. The Note was funded by the Investor on March 28, 2023. On April 17, 2023, 1800 Diagonal filed a Notice of Default for not filing the Form 10-K for 2022 on a timely basis, the result of which was to increase the debt by \$27,225.

The Investor may in its option, at any time following an Event of Default, as defined in the Note, convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock at a conversion price per share equal to 75% of the average of the three lowest closing prices of our common stock during the 15 trading days prior to the date of conversion. Additionally, the Company agreed to reserve five times the number of shares of our common stock which may always be issuable upon conversion of the Note.

One44 Capital LLC

On March 28, 2023, Growlife, Inc. a Delaware corporation (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with One44 Capital, LLC, a Nevada limited liability company (the "Investor"), pursuant to which the Company sold One44 Capital a promissory note in the principal amount of \$150,000 (the "Note"). The Note carries an interest rate of ten percent (10%) (the "Interest Rate") (24% upon the occurrence of an event of default) and has a maturity date of March 28, 2024. The Note included an original issue discount of \$15,000 and transaction expenses of \$6,750 and was purchased for an aggregate of \$128,250. The Note was funded by the Investor on March 28, 2023.

The Investor may in its option, at any time following six months from the issuance date convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock at a conversion price per share equal to 60% of the lowest closing prices of our common stock during the 20 trading days prior to the date of conversion. Additionally, the Company agreed to reserve 19,230,700 shares of our common stock which may always be issuable upon conversion of the Note.

Individuals

Between May 3 and June 16, 2023, the Company entered into Convertible Notes with three individual investors for a total of \$250,000. The Notes bear interest at the rate of ten percent (10%) per year and are due one year from the issuance date.

The Investors may at its option, at any time from the issuance date convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock at a conversion price per share equal to \$0.04 per share. During the six months ended June 30, 2023, individuals converted principal and interest of \$116,892 into 3,734,282 shares of our common stock at an average per share conversion price of \$0.04.

NOTE 9 – DERIVATIVE LIABILITIES

The Convertible Notes payable include a conversion feature that pursuant ASC 815 "Derivatives and Hedging", has been identified as an embedded derivative financial instrument and which the Company accounts for under the fair value method of accounting. In additions, certain warrants issued by the Company also meet the criteria that requires them to be accounted for as derivative liabilities.

Certain convertible notes payable convert at a discount to the market price of common stock. In addition, for many of these notes the exercise price of the embedded conversion feature are adjustable based upon issuances of other securities with lower purchase price. As a result, management has deemed that these embedded conversion features meet the requirements to be accounted as derivatives. The debt is convertible at range of 75% to 50% of the fair value of the Company's common stock requiring the conversion feature to be bifurcated from the host debt contract and accounting for separately as a derivative, resulting in periodic revaluations. The notes underlying the derivatives are short term in nature and generally converted to stock in less than one year. The derivative is valued at period end with the key inputs being current stock price and the conversion feature.

The derivative liabilities amounted to \$3,614,677 and \$1,961,846 as of June 30, 2023 and 2022, respectively.

Derivative liabilities for the six months ended was as follows:

		For the Six Months Ended						
	Ju	ne 30, 2023	Ju	ne 30, 2022				
Balance, December 31	\$	2,689,982	\$	1,698,272				
Additions		960,834		315,669				
Conversions		(322,769)		(442,164)				
Change in fair value		286,630		390,069				
Balance, June 30	\$	3,614,677	\$	1,961,846				

NOTE 10 - EQUITY

Authorized Capital Stock

The Company an aggregate 750,000,000 authorized shares consisting of: (i) 740,000,000 shares of common stock, par value \$0.0001 per share, and (ii) 10,000,000 shares of preferred stock, par value \$0.0001 per share.

On October 7, 2022, FINRA (the Financial Industry Regulatory Authority) announced the Reverse Stock Split of 150-for-1 of the Company's common stock. Outstanding shares for all periods of 2022 recognize the impact of this reverse split.

A holder of common stock is entitled to one vote per share of common stock. The holders of common stock have no conversion, redemption or preemptive rights, and shall be entitled to receive dividends when, as, and if declared by the board of directors.

For the six months ended June 30, 2022, the Company had the following common stock transactions:

- \$480,300 of convertible debt was converted into 343,785 shares of common stock in accordance with the terms of the convertible debt agreements.
- 50,000 shares of common stock were issued as a commitment fee to secure additional debt, the shares were valued at fair
 value at the date of issuance.

For the six months ended June 30, 2023, the Company had the following common stock transactions:

- \$641,560 of convertible debt was converted into 13,365,884 shares of common stock in accordance with the terms of the
 convertible debt agreements.
- 3,125,000 shares of common stock were issued as a commitment fee to secure additional debt, the shares were valued at fair
 value at the date of issuance.
- 4,280,373 shares of common stock were issued for services, the shares were valued at fair value at the date of issuance.
- 583,333 shares of common stock were issued for the cashless exercise of warrants in accordance with the terms of the
 warrant agreement. As a result, \$51,593 of the derivative liability was reduced.
- 5,923,345 shares of common stock were issued in connection with the acquisition of the Bridgetown Mushrooms business, the shares were valued at fair value at the date of issuance.

As of June 30, 2023 and December 31, 2022 the Company had issued and outstanding 35,561,189 and 7,083,254 shares, respectively, of common stock.

Preferred Stock

On November 17, 2022, the Company designated 1,800 shares of its authorized and unissued preferred stock as Series A Preferred Stock and filed a Certificate of Designation of Series A Convertible Preferred Stock of GrowLife, Inc. (the "Series A Certificate of Designation") with the Delaware Secretary of State.

Each share of Series A Preferred Stock is convertible into 1,000 shares of Common Stock (subject to adjustment as provided in the Series A Certificate of Designation) at any time at the option of the holder, provided that the holder is prohibited from converting the Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of Common Stock then issued and outstanding, (the "Beneficial Ownership Limitation"), provided that the holder may reset the Beneficial Ownership Limitation to a higher or lower number (not to exceed 9.99% of the total number of Common Shares issued and outstanding immediately after giving effect to a conversion) upon providing written notice to the Company. Any such notice providing for an increase to the Beneficial Ownership Limitation will be effective 61 days after delivery to the Company.

In the event of the Company's liquidation, dissolution, or winding up holders of Series A Preferred, any such distribution shall be distributed among the holders of Common Stock, Series A Preferred and any other class or series of preferred stock of the Corporation entitled to participate with the Common Stock in a liquidating distribution, *pro rata* in proportion to the shares of Common Stock then held by them and the maximum number of shares of Common Stock which they would have the right to acquire upon conversion of shares of Series A Preferred, assuming the full conversion of all Common Stock Equivalents then held by them.

Shares of Series A Preferred Stock generally have no voting rights, except as required by law.

Holders of Series A Preferred Stock are not entitled to receive any dividends payable to holders of Common Stock.

As of June 30, 2023 and December 31, 2022, the Company had issued and outstanding 600 shares and 1,800 shares, respectively, of preferred stock. Such shares were issued as a portion of a commitment fee to obtain financing and are convertible into 1,800,000 shares of common stock. During the three months ended June 30, 2023, 1,200 shares of preferred stock were converted into 1,200,000 shares of common stock. This was done within the terms of the certificate of designation and therefore no gain or loss was recorded on the transaction

Voting Common Stock

Holders of the Company's common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. On all other matters, the affirmative vote of the holders of a majority of the stock present in person or represented by proxy and entitled to vote is required for approval, unless otherwise provided in our articles of incorporation, bylaws or applicable law. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock.

In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

Unless otherwise indicated, all of the following sales or issuances of Company securities were conducted under the exemption from registration as provided under Section 4(2) of the Securities Act of 1933 (and also qualified for exemption under 4(5), formerly 4(6) of the Securities Act of 1933, except as noted below). All of the shares issued were issued in transactions not involving a public offering, are considered to be restricted stock as defined in Rule 144 promulgated under the Securities Act of 1933 and stock certificates issued with respect thereto bear legends to that effect.

The Company has compensated consultants and service providers with restricted common stock during the development of our business and when our capital resources were not adequate to provide payment in cash.

Warrants

The Company had the following warrant activity during the six months ended June 30, 2023:

On February 1, 2023 the Company issued a common stock purchase warrant to Fourth Man LLC for the purchase of 625,000 shares of the Company's common stock. The exercise price is \$0.08 per share and is exercisable for a term of five years. On April 1, 2023 Fourth Man exercised its right to a cashless exercise of the warrant which resulted in the Company issuing 583,333 shares of common stock for these warrants. The estimated total value of the warrants using the Binomial pricing model described in Derivative Financial Instruments of Note 3 was \$51,593.

The Company had the following warrant activity during the year ended December 31, 2022:

On May 18, 2022 the Company issued a common stock purchase warrant to AJB Capital for the purchase of 6,000,000 shares of the Company's common stock. The exercise price is \$0.05 per share and is exercisable for a term of five years. The warrant purchase agreement protected AJB Capital from the impact of any reverse split but afforded them the benefit of any stock split. The warrant were included in the determination of the derivative liability.

On November 2, 2022 the Company issued a common stock purchase warrant to Quick Capital for the purchase of 1,911,111 shares of the Company's common stock. The exercise price is \$0.05 per share and is exercisable for a term of five years. The warrant were included in the determination of the derivative liability.

As the exercise price of the warrants issued to AJB Capital and Quick Capital are adjustable based upon based upon the issuance of other securities with lower purchase prices, management has deemed these warrants should be accounted for as a derivative. See Note 8 for further information on derivative liabilities.

	Six Months Ended June 30, 2024	For the Year Ended December 31, 2023
Beginning balance	7,911,111	1,039,501
Issued	625,000	7,911,111
Exercised	(583,333)	_
Forfeited	(41,667)	(1,039,501)
Ending balance	7,911,111	7,911,111

NOTE 11 - STOCK OPTIONS

Description of Stock Option Plan

On November 5, 2021, at our annual shareholder meeting the Second Amended and Restated 2017 Stock Incentive Plan was adopted to increase the shares issuable under the plan from 1,333,333 to 75,000,000 shares. All terms of the Plan shall remain the same with the exception of the amount of shares reserved for issuance under the Plan. We have 75,000,000 shares available for issuance under the Second Amended and Restated 2017 Stock Incentive Plan. The Company had no outstanding stock options as of June 30, 2023 or at December 31, 2022.

NOTE 12 - COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS

Legal Proceedings

From time to time, the Company may become subject to various legal proceedings that are incidental to the ordinary conduct of the Company's business. Although we cannot accurately predict the amount of any liability that may ultimately arise with respect to any of these matters, it makes provision for potential liabilities when it deems them probable and reasonably estimable. These provisions are based on current information and may be adjusted from time to time according to developments.

As of September 30, 2019, the Company closed retail stores in Portland, Maine, Encino, California and Calgary, Canada. The Company has recorded restructuring reserves related to the store closures. The Company cannot determine the outcome of these proceedings.

On April 23, 2021, the Company was notified that it was in default on its notes held by Silverback Capital Corporation. The reason for the default was the Company's inability to provide the reserve share requirement as specified in the notes. The penalty for the reserve share default was an increase in the outstanding note balances by 15%, an increase in the conversion discount by 5%, and a default interest rate on the outstanding note balances of 22%. The company recorded such amounts as debt extinguishment and as all amount were considered due on demand, such amount was expensed.

As a result of the reserve share default, on May 7, 2021, Silverback demanded immediate payment in full of all their notes. On May 10, 2021, when Silverback had not been paid in full, Silverback presented another default notice for lack of payment. The penalty for the non-payment default was an increase in the outstanding note balances by another 15%, an additional increase in the conversion discount by 5%, and a default interest rate on the outstanding note balances of 22%. The company recorded such amount as debt extinguishment and as all amounts were considered due in demand, such amount was immediately expensed.

On May 10, 2023, Mr. Mickelson filed a Motion for Summary Judgment in the original lawsuit against Growlife and the former CEO, seeking 100% of the damages claimed for breach of contract, and is no longer pursuing rescission. Growlife filed its opposition to the complaint on June 9, 2023. Growlife intends to vigorously defend itself against the Motion.

NOTE 13 – INCOME TAXES

The Company has incurred losses since inception, which have generated net operating loss carryforwards. The net operating loss carryforwards arise solely from United States sources.

The Company has net operating loss carryforwards of approximately \$25.8 million of which \$14.1 million related to years prior to 2018 which expire in 2022 through 2038. Because it is more likely than not that sufficient tax earnings will be generated to utilize the net operating loss carryforwards, the deferred tax asset related to the net operating loss carryforwards has a corresponding 100% valuation allowance. Additionally, under the Tax Reform Act of 1986, the amounts of, and benefits from, net operating losses may be limited in certain circumstances, including a change in control.

Section 382 of the Internal Revenue Code generally imposes an annual limitation on the amount of net operating loss carryforwards that may be used to offset taxable income when a corporation has undergone significant changes in its stock ownership. There can be no assurance that the Company will be able to utilize any net operating loss carryforwards in the future. The Company is subject to possible tax examination for the years 2014 through 2021.

NOTE 14 – SUBSEQUENT EVENTS

The Company evaluates subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements are available.

These were the material events after June 30, 2023:

Common Share Issuance

On July 7, 2023 the Company issued 600,000 shares of common stock to Arin Funding for services. The shares were valued at \$0.03 per share or \$18,000.

On January 19, 2024 the Company issued 2,500,000 shares of common stock to Coventry Enterprises, LLC on the conversion of \$1,125 of Convertible Debt at a price of \$0.00045. The value of the shares at the date of conversion was \$0.0005 per share.

Convertible Promissory Notes

On various dates between July 7, 2023 and September 19, 2023, the Company entered various convertible promissory notes with five individuals amounting to \$215,000 and with Fourth Man for \$37,500. The notes for three of the individuals also provide for Warrants to purchase shares of the Company's common stock for \$0.01 per share and have a term of five years from issuance date. The note for 4th Man includes a Warrant to purchase 5,629,500 shares of the Company's common stock for \$0.01 per share and have a term of five years from issuance date. The notes to individuals carry 10% interest rate and the Fourth Man note carry 16% interest rate, and all have maturity dates of one year from issuance. The notes and accrued and unpaid interest are convertible at the option of the holder prior to maturity date at \$0.04 per share.

On various dates between October 27, 2023 and January 3, 2024, the Company entered into various convertible promissory notes with various accredited investors amounting to \$856,500. The notes also provide for 21,787,500 Warrants to purchase shares of the Company's common stock for \$0.01 per share and have a term of five years from issuance date. The notes carry 10% interest rate, have maturity dates of one year from issuance. The notes and accrued and unpaid interest are convertible at the option of the holder prior to maturity date at \$0.04 per share.

On various dates between January 9, 2024 and June 30, 2024, the Company entered into various convertible promissory notes with various accredited investors amounting to \$335,000. The notes also provide for 8,375,000 Warrants to purchase shares of the Company's common stock for \$0.01 per share and have a term of five years from issuance date. The notes carry 10% interest rate, have maturity dates of one year from issuance. The notes and accrued and unpaid interest are convertible at the option of the holder prior to maturity date at \$0.04 per share.

Notes Payable

On various dates between April 19, 2024 and June 30, 2024, the Company entered into various promissory notes with various accredited investors amounting to \$75,500 (\$55,500 of which was from the CEO of the Company). The notes carry 10% interest rate, have maturity dates of one year from issuance.

On various dates between March 21, 2024 and May 7, 2024, the Company entered into promissory notes with two commercial lenders amounting to \$71,400. The notes carry 40% interest rate, have maturity dates of less than one year from issuance.

Conversions

On various dates between July 7 and November 14, 2023, convertible debt holders converted principal and interest of \$103,100 into 16,123,466 shares of the Company's common stock at an average per share conversion price of \$0.006.

On August 2, 2023 Coventry converted the remaining 600 preferred shares into 600,000 shares of the Company's common stock.

Legal Complaint

On January 24, 2024 Coventry Enterprises filed a Complaint in the Superior Court in the State of Delaware alleging breach of contract and seeking damages of \$265,811. The Company responded on February 23, 2024 disputing the amount of damages.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GrowLife spent much of 2022 extensively seeking new business expansion opportunities for the Company while continuing to explore options to resolve and settle the EZ-CLONE litigation. On September 2, 2022 we announced our agreement with Bridgetown Mushrooms and the Company's forward looking strategy. It is the Company's belief that moving into the mushroom cultivation space is a natural progression for GrowLife. On January 7, 2023 completed the purchase of Bridgetown Mushroom's assets and the assumption of secured debt. The work with Bridgetown is the perfect illustration of how we are leveraging our long history of cultivation expertise to bring innovative and high-demand products to emerging markets. We believe our shareholders may benefit by GrowLife moving forward and capitalizing on the opportunities available to the Company.

Employees

As of June 30, 2023, we had 12 full-time and part-time employees. None of our employees are subject to a collective bargaining agreement or represented by a trade or labor union.

Competition

Competition is made up primarily of local or regional mushroom growers who mostly supply restaurants, distributors and grocery stores with gourmet mushrooms. These are mostly privately held enterprises. As a result, it is difficult to determine operating performance between the Company and the competition.

Intellectual Property and Proprietary Rights

Our intellectual property consists of brands and their related trademarks and websites, customer lists and affiliations, product know-how and technology, and marketing intangibles.

Our other intellectual property is primarily in the form of trademarks and domain names. We also hold rights to several website addresses related to our business including websites that are actively used in our day-to-day business such as www.shopgrowlife.com, www.growlifeinc.com and www.bridgetown-mushrooms.com. We have a policy of entering into confidentiality and non-disclosure agreements with our employees, some of our vendors and customers as necessary.

OUR COMMON STOCK

As of March 17, 2020, we commenced trading on the OTCQB Market ("OTCQB") after successfully up-listing from the OTC Pink Market.

RESULTS OF OPERATIONS

The following table presents certain consolidated statement of operations information and presentation of that data as a percentage of change from period-to-period.

THREE MONTHS ENDED JUNE 30, 2023, AS COMPARED TO THE THREE MONTHS ENDED JUNE 30, 2022

Three Months ended June 30, (Dollars in thousands)

	(Donars in mousumus)						
		2023		2022		Variance	% Variance
Net revenue	\$	147	\$	_	\$	147	100%
Cost of good sold		(44)		_		(44)	100%
Gross profit		103		_		191	100%
Operating expenses		(678)		(363)		(315)	87%
Operating (loss)		(575)		(363)		(124)	34%
Other expense							
Change in fair value of derivative		(527)		(312)		(215)	69%
Interest expense, net		(1,787)		(235)		(1,552)	660%
Impairment of intangible assets		(553)		_		(553)	100%
Gain(Loss) on forgiveness/settlement of debt		65		(318)		383	-120%
Total other expenses		(2,802)		(865)		(1,937)	224%
Net (Loss) from continuing operations		(3,377)		(1,228)		(2,149)	175%
Income (Loss) from discontinued operations net of taxes		_		(456)		(1,963)	430%
Net (loss)	\$	(3,377)	\$	(1,684)	\$	(1,693)	101%

Net Revenue

Net revenue for the three months ended June 30, 2023 was \$147,000 representing sales by Bridgetown Mushrooms.

Cost of Goods Sold

Cost of sales for the three months ended June 30, 2023 was \$44,000 representing the cost of products sold by Bridgetown Mushrooms.

Gross profit was \$103,00 for the three months ended June 30, 2023. The gross profit percentage was 70% for the three months ended June 30, 2023.

Operating Expenses

Operating expenses for the three months ended June 30, 2023, were \$678,000 as compared to \$363,000 for the three months ended June 30, 2022. The increase in expenses was due to the addition of eight fulltime and one part-time employees at Bridgetown Mushrooms as well as rent, sales and marketing expenses and an increase in travel expenses.

Other Expenses

Other expenses for the three months ended June 30, 2023, were \$2,802,000 as compared to \$865,000 for the three months ended June 30, 2022. The increase in other income (expense) for the three months ended June 30, 2023 compared to the same period the prior year, included (i) an increase in the change in fair value of the derivative liability of \$215,000; (ii) an increase in net interest expense of \$1,552,000, (iii) impairment of intangible assets of \$553,000 which was determined by management, and (iv) change in gain/loss on forgiveness/settlement of debt of \$383,000. The change in derivative liability is the non-cash change in the fair value and relates to our derivative instruments. The increase in non-cash interest related to accrued interest expense and default penalties on our notes payable.

Net Loss

Net loss from continuing operations for the three months ended June 30, 2023 was \$3,377,000 as compared to \$1,228,000 for the three months ended June 30, 2022, for the reasons discussed above. The net loss for the three months ended June 30, 2022 included the loss from discontinued operations of \$456,000.

SIX MONTHS ENDED JUNE 30, 2023, AS COMPARED TO THE SIX MONTHS ENDED JUNE 30, 2022

Six Months ended June 30, (Dollars in thousands)

	(Dotter's in thousants)					
	2023		2022		\$ Variance	% Variance
Net revenue	\$	227	\$		\$ 227	100%
Cost of good sold		(85)			(85)	100%
Gross profit		142		_	312	100%
Operating expenses		(1,327)		(620)	(707)	114%
Operating (loss)		(1,185)		(620)	(395)	64%
Other expense						
Change in fair value of derivative		(286)		(390)	104	-27%
Interest expense, net		(2,445)		(371)	(2,074)	559%
Impairment of intangible assets		(553)		_	(553)	100%
Gain(Loss) on forgiveness/settlement of debt		75		(171)	246	-144%
Total other expenses		(3,209)		(932)	(2,277)	244%
Net (Loss) from continuing operations		(4,394)		(1,552)	(2,842)	183%
Income (Loss) from discontinued operations net of taxes				(741)	741	-100%
Net (loss)	\$	(4,394)	\$	(2,293)	\$ (2,101)	92%

Net Revenue

Net revenue for the six months ended June 30, 2023 was \$227,000 representing sales by Bridgetown Mushrooms from the date of the purchase of assets of the business on January 7, 2023.

Cost of Goods Sold

Cost of sales for the six months ended June 30, 2023 was \$85,000 representing the cost of products sold by Bridgetown Mushrooms from the date of the purchase of assets of the business on January 7, 2023.

Gross profit was \$142,00 for the six months ended June 30, 2023. The gross profit percentage was 63% for the three months ended June 30, 2023.

Operating Expenses

Operating expenses for the six months ended June 30, 2023, were \$1,327,000 as compared to \$620,000 for the three months ended June 30, 2022. The increase in expenses was due to the addition of eight fulltime and one part-time employees at Bridgetown Mushrooms as well as rent, sales and marketing expenses and an increase in travel expenses.

Other Expenses

Other expenses for the six months ended June 30, 2023, were \$3,209,000 as compared to \$932,000 for the six months ended June 30, 2022. The increase in other income (expense) for the six months ended June 30, 2023 compared to the same period the prior year, included (i) a decrease in the change in fair value of the derivative liability of \$104,000; (ii) an increase in net interest expense of \$2,074,000, (iii) an increase in impairment of intangibles of \$553,000 as determined by management, and (iv) a decrease in gain/loss on forgiveness/settlement of debt of \$246,000. The change in derivative liability is the non-cash change in the fair value and relates to our derivative instruments. The increase in non-cash interest related to accrued interest expense and default penalties on our notes payable. The loss on debt conversions related debt conversion of our notes payable at prices below the market price.

Net Loss

Net loss from continuing operations for the three months ended June 30, 2023 was \$4,394,000 as compared to \$1,552,000 for the six months ended June 30, 2022, for the reasons discussed above. The net loss for the six months ended June 30, 2022 included the loss from discontinued operations of \$741,000.

LIQUIDITY AND CAPITAL RESOURCES

We adopted the Financial Accounting Standards Board's ("FASB") Accounting Standard Codification ("ASC") Topic 205-40, Presentation of Financial Statements - Going Concern, which requires that management evaluate whether there are relevant conditions and events that, in the aggregate, raise substantial doubt about the entity's ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.

The accompanying financial statements have been prepared assuming that we will continue as a going concern. However, since inception, we have sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of June 30, 2023, we had an accumulated deficit of \$169 million, cash and cash equivalents of \$5,000 and a working capital deficit of \$2,198,000, excluding derivative liability, convertible debt, and right of use assets and liability. Net cash used in operating activities was \$734,000 for the six months ended June 30, 2023.

The Company believes it will require additional funding in order to execute its business plans

To fund further GrowLife operations, we will need to raise additional capital. We may obtain additional financing in the future through the issuance of its common stock, or through other equity or debt financings. Our ability to continue as a going concern or meet the minimum liquidity requirements in the future is dependent on its ability to raise significant additional capital, of which there can be no assurance. If the necessary financing is not obtained or achieved, we will likely be required to reduce its planned expenditures, which could have an adverse impact on the results of operations, financial condition and our ability to achieve its strategic objective. There can be no assurance that financing will be available on acceptable terms, or at all. The financial statements contain no adjustments for the outcome of these uncertainties. These factors raise substantial doubt about our ability to continue as a going concern and have a material adverse effect on our future financial results, financial position and cash flows.

See Note 14 - Subsequent Events for additional debt raised during the third and fourth quarters of 2023.

Operating Activities

Net cash used in operating activities for the six months ended June 30, 2023, was \$734,000. This amount was primarily related to a (i) net loss of \$4,394,000; and (ii) a net working capital increase of \$215,000; (iii) depreciation and amortization of \$130,000; (iv) impairment of intangibles of \$553,00; (v) accrued interest and penalties of \$2,183,000; (vi) change in derivative liability of \$286,830; and (vii) gain on forgiveness/extinguishment of debt of \$75,000.

Investing Activities

Net cash used in investing activities for the six months ended June 30, 2023, was \$4,000. The amount related to purchase of computers.

Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2023, was \$649,000 compared to \$979,000 for the six months ended June 30, 2022. The amount related to proceeds from various notes payable of \$862,000 offset by repayment of notes payable of \$213,000 for the six months ended June 30, 2023. The amount related to proceeds from various notes payable of \$1,004,000 offset by repayment of notes payable of \$25,000 for the six months ended June 30, 2022.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

This item is not applicable.

ITEM 4. CONTROLS AND PROCEDURES

a) Evaluation of Disclosure Controls and Procedures

We conducted an evaluation under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended ("Exchange Act"), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive and principal financial officers concluded as of June 30, 2023, that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses in our internal controls over financial reporting discussed immediately below.

Identified Material Weaknesses

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

Management identified the following material weaknesses during its assessment of internal controls over financial reporting:

Audit Committee:

The current Audit Committee has one independent director, and the Chairman is an interim Named Executive Officer. In early January 2021 an additional independent director resigned from the board and audit committee. We expect to expand this committee during 2022 once a qualified candidate is identified.

Personnel:

We do not employ a full time Chief Financial Officer. Mr. Dohrmann has served as both Chief Executive Officer and Interim Chief Financial Officer since July 1, 2022. We utilize a consultant to assist with our financial reporting. There are limited personnel to assist with the accounting and financial reporting function, which results in: (i) a lack of segregation of duties and (ii) controls that may not be adequately designed or operating effectively and have not been formally documented. Despite the existence of material weaknesses, the Company believes the financial information presented herein is materially correct and fairly presents the financial position and operating results of the six months ended June 30, 2023, in accordance with GAAP.

Contractual Terms and Obligations

The Company entered into various financing agreements involving stock purchase agreements, notes and warrants. The terms of these legal instruments contain complex legal terms, conditions and calculations. Managements understanding of certain terms and conditions of the warrant agreements was not adequate to insure proper accounting and disclosure of the warrant terms.

(b) Management's Report on Internal Control Over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed by, or under the supervision of, our CEO and CFO, or persons performing similar functions, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America (GAAP). Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Management assessed the effectiveness of the Company's internal control over financial reporting as of June 30, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in the 2013 *Internal Control-Integrated Framework*. Based on its evaluation, management has concluded that the Company's internal control over financial reporting was not effective as of June 30, 2023.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. A control system, no matter how well designed and operated can provide only reasonable, but not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their cost.

c) Changes in Internal Control over Financial Reporting

The Company has a small accounting and finance team. Consulting services provided by independent consultants have been an important element of internal control during this transition. There were no other changes which were identified in connection with our management's evaluation required by paragraph (d) of rules 13a-15 and 15d-15 under the Exchange Act, that materially affected, or is reasonably likely to have a materially affect, on our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become subject to various legal proceedings that are incidental to the ordinary conduct of its business. Although we cannot accurately predict the amount of any liability that may ultimately arise with respect to any of these matters, it makes provision for potential liabilities when it deems them probable and reasonably estimable. These provisions are based on current information and may be adjusted from time to time according to developments.

On October 15, 2018, we closed the Purchase and Sale Agreement with EZ-CLONE Enterprises, Inc., a California corporation (the "Agreement"). On November 5, 2019, the Company amended the Agreement with one 24.5% shareholder of EZ-CLONE Enterprises, Inc. ("EZ-CLONE"), to extend the date to purchase the remaining 49% of stock of EZ-CLONE in exchange for a 20% extension fee (a total of \$171,000 for the 49% or \$85,500 for each 24.5% shareholder) of the \$855,000 cash payable at the earlier of the closing of \$2,000,000 in funding or nine months (July 2020). The Company did not close the purchase of the remaining 49% of stock of EZ-CLONE by the extended deadline.

On September 15, 2020, the Company received notice that William Blackburn and Brad Mickelsen ("Plaintiffs"), minority shareholders of EZ-CLONE Enterprises, Inc., a majority owned subsidiary of the Company, filed a complaint against the Company and its officers in the Superior Court of California, County of Sacramento ("Complaint") for claims related to breach under the Purchase and Sale Agreement dated October 15, 2018 between the Company and Plaintiffs. The Complaint also alleges that the Company and its Officers made certain false representations and other claims to consummate the Transaction and as a result has failed to complete the second closing as required under Purchase and Sale Agreement. As of December 4, 2020, the Company's officers were dismissed from the case. The complaint sought rescission of the Purchase and Sale Agreement, unspecified damages in excess of ten thousand dollars, and other equitable relief. See Note 12 for description of Legal Proceedings.

On September 15, 2020, the Company filed a notice of removal with the California Superior Court, County of Sacramento and the United States District Court for the Eastern District of California. The case was removed to Federal District Court for the Eastern District of California and Plaintiffs filed an Ex Parte Application for TRO and an Order for Preliminary Injunction with the Federal Court. The TRO was granted on September 16, 2020 and a preliminary injunction hearing was scheduled for September 29, 2020. After reviewing all pleadings and oral arguments at the hearing, the Court issued a ruling granting Plaintiffs' request for a preliminary injunction.

On December 29, 2022, the Company entered into a Settlement Agreement and Mutual General Release ("SAMGA") with Mr. Blackburn whereby: (i) both parties agreed to settle all disputes and potential disputes, (ii) EZ-CLONE assumes all obligations relating to the warehouse lease, (iii) 32.7% of the stock held by the Company was retired, (iv) 3.9% of the stock held by the Company was transferred to Mr. Blackburn, and (v) the Company received anti-dilution rights for a period of five years. As a result, the Company's ownership percentage has decreased from 51% to 19.6% and Mr. Blackburn ownership percentage has increased from 24.5% to 51%, and Mr. Mickelsen ownership percentage increased from 24.%% to 29.4%. Mr. Mickelsen refused to participate in negotiating the SAMGA.

On May 10, 2023, Mr. Mickelson filed a Motion for Summary Judgment in the original lawsuit against Growlife and the former CEO, seeking 100% of the damages claimed for breach of contract, and is no longer pursuing rescission. Growlife filed its opposition to the complaint on June 9, 2023. Growlife intends to vigorously defend against the Motion.

ITEM 1A. Risk Factors.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unless otherwise indicated, all of the following sales or issuances of Company securities were conducted under the exemption from registration as provided under Section 4(2) of the Securities Act of 1933 (and also qualified for exemption under 4(5), formerly 4(6) of the Securities Act of 1933, except as noted below). All of the shares issued were issued in transactions not involving a public offering, are considered to be restricted stock as defined in Rule 144 promulgated under the Securities Act of 1933 and stock certificates issued with respect thereto bear legends to that effect.

We have compensated consultants and service providers with restricted common stock during the development of our business and when our capital resources were not adequate to provide payment in cash.

During the six months ended June 30, 2023, we had the following sales of unregistered sales of equity securities:

- 13,365,884 shares were issued upon the conversion of debt.
- 4,280,373 shares were issued for services
- 3,125,000 shares were issued as a commitment fee for the procurement of debt
- 5,923,345 shares were issued for the purchase of the assets of Bridgetown Mushrooms

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Default notices were provided to the Company by 1800 Diagonal on April 17, 2023 for failure by the Company to timely file its Form 10-K for the calendar year 2022. Such default resulted in the increase of principal and interest amounting to \$102,514 on the outstanding debt to 1800 Diagonal. On April 18,2023 Silverback issued a default notice to the Company for failure by the Company to timely file it For 10-K for the calendar year 2022. Such default resulted in the increase of principal amounting to \$49,757.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

The exhibits required to be filed herewith by Item 601 of Regulation S-K, as described in the following index of exhibits, are attached hereto unless otherwise indicated as being incorporated by reference, as follows:

(a) Exhibits

Exhibit No.	Description
3.1	Certificate of Incorporation. Filed as an exhibit to the Company's Form 10-SB General Form for Registration of Securities of Small Business Issuers filed with the SEC on December 7, 2007, and hereby incorporated by reference.
<u>3.2</u>	First Amendment to Second Amended and Restated Bylaws Amendment, dated August 6, 2022 incorporated herein by reference.
3.3	Certificate of Amendment of Certificate of Incorporation of GrowLife, Inc. dated October 23, 2017 to increase the authorized shares of Common Stock from 3,000,000,000 to 6,000,000,000 shares. Filed as an exhibit to the Company's Form 8-K and filed with the SEC on October 24, 2017, and hereby incorporated by reference.
<u>3.4</u>	Amendment to Articles of Incorporation dated November 20, 2019. Filed as an exhibit to the Company's Form 8-K and filed with the SEC on November 26, 2019, and hereby incorporated by reference.
3.5	Certificate of Amendment of Certificate of Incorporation of GrowLife, Inc. dated November 8, 2021, to increase the authorized shares of Common Stock from 120,000,000 to 740,000,000 shares. Filed as an exhibit to the Company's Form 10-Q filed with the SEC on November 23, 2021.
3.6	Amendment to Articles of Incorporation citing Reverse Stock Split, dated September 29, 2022
<u>3.7</u>	Certificate of Designation of Series A Convertible Preferred Stock of GrowLife, Inc., Filed as an exhibit to the Company's Form 8-K filed with the SEC on November 28, 2022.
31.1	Certification of Principal Executive Officer Pursuant to Rule 13a-14 *
31.2	Certification of Principal Financial Officer Pursuant to Rule 13a-14 *
32.1	CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act *
32.2	CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act *
101.INS *	Inline XBRL Instance Document
101.SCH *	Inline XBRL Taxonomy Extension Schema Document
101.CAL *	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB *	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE *	Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF *	Inline XBRL Taxonomy Extension Definition Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
*Filed Herewit	h.

SIGNATURES

In accordance with Section 13 or 15(d) requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GROWLIFE, INC.

(Registrant)

Date: August 23, 2024 By: /s/ David Dohrmann

David Dohrmann Chief Executive Officer and President (Principal Executive Officer); Interim Chief Financial Officer

- 32 -

SECTION 302 CERTIFICATIONS

- I, David Dohrmann, certify that:
- 1. I have reviewed this quarterly report on Form 10-Q of GrowLife, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(a) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 23, 2024
/s/ David Dohrmann
David Dohrmann
Chief Executive Officer

SECTION 302 CERTIFICATIONS

- I, David Dohrmann, certify that:
- 1. I have reviewed this quarterly report on Form 10-Q of GrowLife, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(a) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 23, 2024

/s/ David Dohrmann

David Dohrmann

Interim Chief Financial Officer

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GrowLife, Inc. (the "Company") on Form 10-Q for the quarter ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, David Dohrmann, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

This certificate is being made for the exclusive purpose of compliance by the Principal Executive and Financial and Accounting Officer of the Company with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002, and may not be disclosed, distributed or used by any person or for any reason other than as specifically required by law.

/s/ David Dohrmann	
David Dohrmann Chief Executive Officer	

August 23, 2024

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GrowLife, Inc. (the "Company") on Form 10-Q for the quarter ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, David Dohrmann Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

This certificate is being made for the exclusive purpose of compliance by the Principal Executive and Financial and Accounting Officer of the Company with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002, and may not be disclosed, distributed or used by any person or for any reason other than as specifically required by law.

/s/ David Dohrmann
David Dohrmann
Interim Chief Financial Officer

August 23, 2024